--- a
+++ b/matching/trials/NCT01162902.xml
@@ -0,0 +1,196 @@
+<?xml version="1.0" encoding="UTF-8"?>
+<clinical_study rank="112636">
+  <!-- This xml conforms to an XML Schema at:
+    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
+ and an XML DTD at:
+    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
+  <required_header>
+    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
+    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
+    <url>https://clinicaltrials.gov/show/NCT01162902</url>
+  </required_header>
+  <id_info>
+    <org_study_id>ABC Trial</org_study_id>
+    <nct_id>NCT01162902</nct_id>
+  </id_info>
+  <brief_title>Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation</brief_title>
+  <official_title>Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation</official_title>
+  <sponsors>
+    <lead_sponsor>
+      <agency>Seoul National University Hospital</agency>
+      <agency_class>Other</agency_class>
+    </lead_sponsor>
+  </sponsors>
+  <source>Seoul National University Hospital</source>
+  <oversight_info>
+    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
+    <has_dmc>Yes</has_dmc>
+  </oversight_info>
+  <brief_summary>
+    <textblock>
+      Treatments for stable angina includes drug therapy such as calcium-channel blocker, beta
+      blocker, and ACEI/ARB. To obtain good prognosis in patients with coronary artery
+      disease,preventing or correcting the progression of atherosclerosis and dyslipidemia is more
+      important than relieving angina symptom. Dysfunction of microvessel is one of the most
+      important factor in patients with coronary artery disease. Recently, we developed the new
+      non-invasive method of evaluating the microvessel in fundus. With this methods, we will
+      compare the effect of each drug (beta blocker, CCB, ARB).
+    </textblock>
+  </brief_summary>
+  <overall_status>Not yet recruiting</overall_status>
+  <start_date>September 2013</start_date>
+  <completion_date type="Anticipated">December 2015</completion_date>
+  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
+  <phase>Phase 4</phase>
+  <study_type>Interventional</study_type>
+  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
+  <primary_outcome>
+    <measure>Wall to lumen ratio of fundus vessel</measure>
+    <time_frame>baseline, 9 months</time_frame>
+    <safety_issue>No</safety_issue>
+    <description>Measurement of change in the ratio of wall thickness to lumen of the fundus vessel from baseline to 9 month follow up</description>
+  </primary_outcome>
+  <secondary_outcome>
+    <measure>lipid parameter</measure>
+    <time_frame>baseline, 9 months</time_frame>
+    <safety_issue>No</safety_issue>
+    <description>Measurement of change in total cholesterol, triglyceride, LDL, small dense LDL, and HDL</description>
+  </secondary_outcome>
+  <secondary_outcome>
+    <measure>Serum markers of inflammation</measure>
+    <time_frame>baseline, 9 months</time_frame>
+    <safety_issue>No</safety_issue>
+    <description>CRP</description>
+  </secondary_outcome>
+  <secondary_outcome>
+    <measure>Change of nitrate need</measure>
+    <time_frame>baseline, 1 months, and 3 months</time_frame>
+    <safety_issue>No</safety_issue>
+    <description>Measure of change of nitrate need</description>
+  </secondary_outcome>
+  <number_of_arms>3</number_of_arms>
+  <enrollment type="Anticipated">150</enrollment>
+  <condition>Stable Angina</condition>
+  <arm_group>
+    <arm_group_label>Diltiazem treated group</arm_group_label>
+    <arm_group_type>Experimental</arm_group_type>
+    <description>Diltiazem 180mg treated group</description>
+  </arm_group>
+  <arm_group>
+    <arm_group_label>Bisoprolol treated group</arm_group_label>
+    <arm_group_type>Active Comparator</arm_group_type>
+    <description>Bisoprolol 5mg treated group</description>
+  </arm_group>
+  <arm_group>
+    <arm_group_label>Candesartan treated group</arm_group_label>
+    <arm_group_type>Active Comparator</arm_group_type>
+    <description>Candesartan 32mg treated group</description>
+  </arm_group>
+  <intervention>
+    <intervention_type>Drug</intervention_type>
+    <intervention_name>Diltiazem treated group</intervention_name>
+    <description>Diltiazem 180mg for 9 months</description>
+    <arm_group_label>Diltiazem treated group</arm_group_label>
+  </intervention>
+  <intervention>
+    <intervention_type>Drug</intervention_type>
+    <intervention_name>Bisoprolol treated group</intervention_name>
+    <description>Bisoprolol 5mg for 9 months</description>
+    <arm_group_label>Bisoprolol treated group</arm_group_label>
+  </intervention>
+  <intervention>
+    <intervention_type>Drug</intervention_type>
+    <intervention_name>Candesartan treated group</intervention_name>
+    <description>Candesartan 32mg for 9 months</description>
+    <arm_group_label>Candesartan treated group</arm_group_label>
+  </intervention>
+  <eligibility>
+    <criteria>
+      <textblock>
+        Inclusion Criteria:
+
+          -  Stable angina patients whose coronary lesions is confirmed by angiography or receives
+             PCI
+
+          -  Unstable Angina/NSTEMI patients who completed PCI for main lesions
+
+          -  Either systolic &gt; 130mmHg or diastolic &gt; 80mmHg, or patients with anti-hypertensive
+             drugs
+
+        Exclusion Criteria:
+
+          -  STEMI patients within one month
+
+          -  Variant Angina
+
+          -  Liver function abnormality or renal failure
+
+          -  History of Hypersensitivity to testing drugs
+
+          -  Severe heart failure(NYHA class&gt;3) or uncorrectable hematologic disease
+
+          -  Woman possible to be pregnant
+
+          -  Uncontrolled diabetes
+
+          -  Expected life span &lt; one year
+      </textblock>
+    </criteria>
+    <gender>Both</gender>
+    <minimum_age>30 Years</minimum_age>
+    <maximum_age>80 Years</maximum_age>
+    <healthy_volunteers>No</healthy_volunteers>
+  </eligibility>
+  <overall_contact>
+    <last_name>Hae-Young Lee, MD, PhD</last_name>
+    <phone>82-10-4528-6160</phone>
+    <email>hylee612@snu.ac.kr</email>
+  </overall_contact>
+  <overall_contact_backup>
+    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
+    <phone>82-2-2072-2226</phone>
+    <email>hyosoo@snu.ac.kr</email>
+  </overall_contact_backup>
+  <location>
+    <facility>
+      <name>Seoul National University Hospital</name>
+      <address>
+        <city>Seoul</city>
+        <country>Korea, Republic of</country>
+      </address>
+    </facility>
+    <status>Not yet recruiting</status>
+    <investigator>
+      <last_name>Hyo-Soo Kim, MD, PhD</last_name>
+      <role>Principal Investigator</role>
+    </investigator>
+    <investigator>
+      <last_name>Hae-Young Lee, MD,PhD</last_name>
+      <role>Sub-Investigator</role>
+    </investigator>
+  </location>
+  <location_countries>
+    <country>Korea, Republic of</country>
+  </location_countries>
+  <verification_date>December 2013</verification_date>
+  <lastchanged_date>December 15, 2013</lastchanged_date>
+  <firstreceived_date>April 30, 2010</firstreceived_date>
+  <responsible_party>
+    <name_title>Hyo-Soo, Kim</name_title>
+    <organization>Seoul National University Hospital</organization>
+  </responsible_party>
+  <is_fda_regulated>No</is_fda_regulated>
+  <has_expanded_access>No</has_expanded_access>
+  <condition_browse>
+    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
+    <mesh_term>Angina, Stable</mesh_term>
+  </condition_browse>
+  <intervention_browse>
+    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
+    <mesh_term>Bisoprolol</mesh_term>
+    <mesh_term>Candesartan</mesh_term>
+    <mesh_term>Candesartan cilexetil</mesh_term>
+    <mesh_term>Diltiazem</mesh_term>
+  </intervention_browse>
+  <!-- Results have not yet been posted for this study                                -->
+</clinical_study>